Comparison · NCT02580240-deaths
Hydrocortisone vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Hydrocortisone vs Placebo: deaths from any cause. Trial comparisons, record NCT02580240-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02580240-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.397 | 0.281 | 0.525 | wilson | |
| Risk in group 2 | 0.317 | 0.213 | 0.442 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0799 | -0.0909 | 0.245 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.25 | 0.768 | 2.04 | log | |
| Odds ratio, group 1 over group 2 | 1.42 | 0.665 | 3.02 | log | |
| Number needed to harm, for one more death from any cause on Hydrocortisone than on Placebo | 12.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Hydrocortisone | Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped). | 23 | 58 | EG001 |
| Group 2 | Placebo | Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar. | 19 | 60 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Adverse Events were classified by onset time （within 60 days after the onset of septic shock）.The adverse events were assessed from date of randomization until 60 days after the onset of septic shock or date of death from any cause, whichever came first, assessed up to 60 days.
Source ClinicalTrials.gov
Trial
- Title
- Initiation of Hydrocortisone for the Treatment of Septic Shock
- NCT number
- NCT02580240
- Phases
- NA
- Conditions
- Septic Shock
- Interventions
- Hydrocortisone, saline
- Lead sponsor
- Northern Jiangsu People's Hospital
- Results first posted
- 2017-08-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02580240?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02580240-deaths